← All trials
NCT04516967
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- May 22, 2023
- Completion date
- May 15, 2025
- First posted
- Aug 18, 2020
- Last posted
- Nov 13, 2020
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dova PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.